Subscribe to our Newsletters !!
Infections pose an everpresent threat to society a
Biotech Fluidics has introduced a durable dual sta
A new COVID-19 variant, BA.3.2, informally called
The sustained tensions between Iran and the United
For a number of years now, healthcare systems glob
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
Glenmark Pharmaceuticals on Monday said its US arm has received tentative approval from the country’s health regulator for its generic Regadenoson injection. Regadenoson injection is given during the preparation for a radiologic examination of blood flow through the heart to test for coronary artery disease.
According to a statement, the tentative approval was granted by the United States Food & Drug Administration to Glenmark Pharmaceuticals Inc., USA (Glenmark). It is for Regadenoson Injection at 0.4 mg/5 mL (0.08 mL) Single-Dose Prefilled Syringe. It is the generic Lexiscan injection at 0.4 mg/5mL (0.08 mg/mL) of Astellas US Inc.
The company cited IQVIATM sales data from the 12-month period ending November 2021 and stated that the Lexiscan(r), 0.4 mg/5 mL (0.08mg/mL) market had achieved an annual sales figure of around USD 659.9 millions. According to the company, its current portfolio includes 172 products that are authorized for distribution in the US market and 47 abbreviated drug applications (ANDAs), which are awaiting approval by the USFDA.
